Evidence map›Paper›PMID 34521813›Full record

Observational studyBlood cancer journal2021

Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab.

C Cattaneo, V Cancelli, L Imberti, K Dobbs, A Sottini, C Pagani, A Belotti, A Re, A Anastasia, V Quaresima and 7 more

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Blood cancer journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Observational
  6. Review
  7. Article
  8. Impact of the COVID-19 pandemic on the diagnosis and treatment of onco-hematologic patients: a discussion paper.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Reinfection with SARS-CoV-2 in a patient undergoing chemotherapy for lymphoma: Case report.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2022
    Article
  15. Article
  16. Article
  17. Article
  18. Anti-SARS-CoV-2 antibody response after 2 and 3 doses of BNT162b2 mRNA vaccine in patients with lymphoid malignancies.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 2 countries.

C CattaneoHematology, ASST Spedali Civili, Brescia, Italy. chiara.cattaneo@asst-spedalicivili.it.ORCID 0000-0003-0031-3237
V CancelliHematology, ASST Spedali Civili, Brescia, Italy.
L ImbertiCREA (AIL Center for Hemato-Oncologic Research), Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy.ORCID 0000-0002-2075-8391
K DobbsLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-3432-3137
A SottiniCREA (AIL Center for Hemato-Oncologic Research), Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy.
C PaganiHematology, ASST Spedali Civili, Brescia, Italy.
A BelottiHematology, ASST Spedali Civili, Brescia, Italy.ORCID 0000-0002-0617-3127
A ReHematology, ASST Spedali Civili, Brescia, Italy.
A AnastasiaHematology, ASST Spedali Civili, Brescia, Italy.
V QuaresimaCREA (AIL Center for Hemato-Oncologic Research), Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy.ORCID 0000-0001-8858-3236
A TucciHematology, ASST Spedali Civili, Brescia, Italy.ORCID 0000-0003-3052-7463
J A ChioriniNational Institute of Dental and Craniofacial Research, NIH, Bethesda, MD, USA.
H C SuLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
J I Cohen *Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD, USA.
P D Burbelo *National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD, USA.
G Rossi *Hematology, ASST Spedali Civili, Brescia, Italy.
L D Notarangelo *Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITNational Institutes of Health · USNational Institute of Dental and Craniofacial Research · US

Funding

Regione Lombardia (Region of Lombardy) Risposta immune in pazienti con COVID-19 e co-morbidità
6 · The paper itself

Abstract

The ability of patients with hematologic malignancies (HM) to develop an effective humoral immune response after COVID-19 is unknown. A prospective study was performed to monitor the immune response to SARS-CoV-2 of patients with follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), chronic lymphoproliferative disorders (CLD), multiple myeloma (MM), or myelodysplastic/myeloproliferative syndromes (MDS/MPN). Antibody (Ab) levels to the SARS-CoV-2 nucleocapsid (N) and spike (S) protein were measured at +1, +3, +6 months after nasal swabs became PCR-negative. Forty-five patients (9 FL, 8 DLBCL, 8 CLD, 10 MM, 10 MDS/MPS) and 18 controls were studied. Mean anti-N and anti-S-Ab levels were similar between HM patients and controls, and shared the same behavior, with anti-N Ab levels declining at +6 months and anti-S-Ab remaining stable. Seroconversion rates were lower in HM patients than in controls. In lymphoma patients mean Ab levels and seroconversion rates were lower than in other HM patients, primarily because all nine patients who had received rituximab within 6 months before COVID-19 failed to produce anti-N and anti-S-Ab. Only one patient requiring hematological treatment after COVID-19 lost seropositivity after 6 months. No reinfections were observed. These results may inform vaccination policies and clinical management of HM patients.

Indexed as

AdultAgedAged, 80 and overAntibodies, ViralAntibody FormationAntibody SpecificityCase-Control StudiesCOVID-19FemaleFollow-Up StudiesHematologic NeoplasmsHospitalizationHumansImmunity, HumoralItalyLongitudinal StudiesAntibodies, ViralRituximab

Identifiers

PMID34521813
PMCPMC8438656
OpenAlexW3199976854

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.